Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

42,492 --------------------- 100,504 51,410 --------------------- --------------------- BioMS Medical Corp. (A Development Stage Corporation) Consolidated Statements of Operations and Comprehensive Loss ------------------------------------------------------------------------- (expressed in thousands of Canadian dollars and shares, except per share amounts) Cumulative from inception to Years December 31, ended December 31, ------------ ------------------- 2008 2008 2007 $ $ $ Research and development Revenue earned from collaboration partner 52,561 52,561 - Research and development expenses (152,085) (46,502) (38,907) ------------ ------------------- (99,524) 6,059 (38,907) General and administrative expenses (42,605) (13,790) (7,490) Amortization of licensing costs (11,755) (1,472) (1,472) Amortization of property and equipment (517) (125) (134) ------------ ------------------- Loss from operations (154,401) (9,328) (48,003) Other income (expense) Investment income 8,779 2,436 1,644 Foreign exchange gain (loss)
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 This ... PHA, PBS, Starch Based Plastics, Regenerated Cellulose, PCL), ... Global Trends and Forecasts to 2019”, defines and ... analysis and forecast of its global volume and ... 54 Figures spread through 178 Slides and in-depth ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in ... announced that its Board of Directors has appointed ... President and member of the Board effective immediately. ... expanded responsibilities within the company, including further developing ... commercialization, manufacturing and finance. , Dr. Carol ...
(Date:10/25/2014)... 2014 Berkshire Corporation, the world ... announce the release of the ValuSeal® IonX™ cleanroom ... contamination containment in critical processing applications. , Recommended ... cleanroom environments, ValuSeal® IonX™ is a laser sealed ... that continues Berkshire’s innovative focus on meeting new ...
(Date:10/25/2014)... YORK , Oct. 24, 2014 ... Inc. (ACCP), a biopharmaceutical company advancing patient care ... 1-for-50 reverse split of its common stock effective ... 24, 2014. PlasmaTech,s common stock will trade on ... and temporary ticker symbol "ACCPD". After 20 days, ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2
... , , , , Multiporator / Electroporator 2510 , , , , ... Transformation Protocol , Protocol No. 4308 915.509 12/2001 , ... , , , , ... , Cell type , Bacteria, gram positive, ...
... , , , , , , , , ... Protocol No. 4308 915.508 12/2001 , , , , , ... , Microorganism , Brucella abortus, ... Bacteria, gram negative, , , ...
... , , , , , , Multiporator / Electroporator 2510 , , ... , Transformation Protocol , Protocol No. 4308 ... , , , , , , ... , , Cell type , ...
Cached Biology Technology:Clostridium botulinum 2Brucella abortus 2Agrobacterium tumefaciens 2
(Date:10/25/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... on the basis of their physical or behavioral patterns. ... traits such as fingerprints, face recognition, DNA, palm print, ... as keystroke patterns and speech pattern/voice recognition. ...
(Date:10/22/2014)... 21, 2014 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its third quarter ended September 30, ... was $6.0 million, an increase of 40% compared to $4.3 ... the third quarter of 2014 was $4.1 million compared to ... income in the current three month period was primarily due ...
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
Breaking Biology News(10 mins):Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... MADISON Failing to see the forest for ... declining health of Wisconsin,s forest ecosystems. Even areas ... as forests are increasingly fragmented by roads and development, ... fields, housing tracts, and strip malls, say University of ...
... rings are acclaimed in representing natural climate archives. ... growth of these annual rings depend mainly on temperature ... slight seasonal variations, the correlation is not so ... for Geosciences and their colleagues of the Australian National ...
... Versartis, Inc., an emerging company developing novel biologics ... presented data for its long-acting product candidates, VRS-317 (hGH-rPEG) ... (IL-1ra-rPEG) for treatment of type 1 and type 2 ... DC. Versartis, through a unique licensing agreement with Amunix, ...
Cached Biology News:Isolated forest patches lose species, diversity 2Isolated forest patches lose species, diversity 3Australia's climate: Drought and flooding in annual rings of tropical trees 2Versartis presents positive preclinical data on 2 product candidates at ENDO 09 2
... The CopyControl™ vector can be induced prior ... vectors provide the stability of single-copy BACs ... or other cloning vectors. The kits provide ... reagents, insert size screening system) necessary to ...
...
... style strip holder is designed for use ... This CLS number is a new product ... number. If showing no availability yet, please ... or contact customer service for assistance. ID ...
Designed for use with all 96-well SPRI reagent kits. Used with round bottom 96-well microplates, and 96-well thermal cycling plates....
Biology Products: